• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? 
    •   QMRO Home
    • William Harvey Research Institute
    • Centre for Endocrinology
    • Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
    •   QMRO Home
    • William Harvey Research Institute
    • Centre for Endocrinology
    • Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

    View/Open
    Published version (243.7Kb)
    Volume
    108
    Pagination
    9 - 13
    DOI
    10.1038/bjc.2012.523
    Journal
    BRITISH JOURNAL OF CANCER
    Issue
    1
    ISSN
    0007-0920
    Metadata
    Show full item record
    Authors
    Bourke, L; Kirkbride, P; Hooper, R; Rosario, AJ; Chico, TJA; Rosario, DJ
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/18031
    Collections
    • Centre for Endocrinology [527]
    Licence information
    Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
    Copyright statements
    & 2013 Cancer Research UK
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.